Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 575 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Study Finds Most Women Who ‘Go Flat’ After Mastectomy Are Happy... January 16, 2021 Could Cholesterol-Lowering Drugs Improve Cancer Immunotherapy? December 10, 2020 FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia September 3, 2021 The RAD51-IF Test Is Feasible for Assessment of the Functional Status... May 7, 2021 Load more HOT NEWS Long-Term Responders with No Evidence of Disease Have Better Survival to... A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... ESMO Publishes First Guidance on the Safe Use of Large Language...
